Evidence map›Paper›PMID 40849031›Full record

ArticleAmerican journal of ophthalmology2025

Hypertransmission and Vision in Aging and Age-Related Macular Degeneration: Longitudinal Data From ALSTAR2.

Will Johnston, Sarah S Kim, Deepayan Kar, Liyan Gao, Mark E Clark, Gerald McGwin, Kenneth R Sloan, Cynthia Owsley, Christine A Curcio, Lukas Goerdt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Will JohnstonFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; Frederick P. Whiddon College of Medicine (W.J.), University of South Alabama, Mobile, Alabama, USA.
Sarah S KimFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Deepayan KarFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Liyan GaoFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Mark E ClarkFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Gerald McGwinFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Kenneth R SloanFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Cynthia OwsleyFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Christine A CurcioFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. Electronic address: cacurcio@gmail.com.
Lukas GoerdtFrom the Department of Ophthalmology and Visual Sciences (W.J., S.S.K., D.K., L.G., M.E.C., G.M., K.R.S., C.O., C.A.C., L.G.), Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Ophthalmology (L.G.), University Hospital Bonn, Bonn, Germany.

Funding

Functionally Validated Structural Endpoints for Early AMDR01EY029595 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURCIO, CHRISTINE A, OWSLEY, CYNTHIA · 2019 to 2023
$4.1M
NEI NIH HHS R01 EY029595
6 · The paper itself

Abstract

purposeTo investigate the presence of hypertransmission (HT) in normal aging, early (e)AMD, and intermediate (i)AMD, changes over 3 years, and the impact of HTs ≥ 250 µm (LHyperTD) on 7 tests of scotopic, mesopic, and photopic vision.

designProspective cohort study. SUBJECTS: Participants of the Alabama Study on Early Age-Related Macular Degeneration 2.

methodsALSTAR2 participants underwent spectral domain optical coherence tomography angiography (OCTA), color fundus photography, and vision testing at baseline and 3-year follow-up. HT presence and stepped diameters in choroidal en face slabs were assessed with custom review software. Only LHyperTD were analyzed at follow-up. AMD was staged via AREDS 9-step. Vision at baseline and follow-up between eyes with and without LHyperTD was analyzed with linear regression.

main outcome measuresPresence, size, and illustrative examples of HT, association with tests of photopic, mesopic and scotopic vision.

resultsBaseline data was available on 460 eyes of 460 patients (mean age 71.5 ± 5.7 years, 277 female; 236 normal, 134 eAMD, 90 iAMD). HT of any size were found in iAMD (86.7%), eAMD (35.1%), and normal (3.8%) eyes, with proportional LHyperTD (13.3% vs 4.2% vs 0.4%, P < .01). For 339 eyes (mean age 71.2 ± 5.8 years, 206 female, 181 normal, 92 eAMD, 66 iAMD), LHyperTD presence significantly increased in normal (P = .01) and iAMD (P < .01) but not in eAMD eyes. At baseline, photopic contrast sensitivity (CS), mesopic CS, and rod intercept time (for rod mediated dark adaptation, RMDA) were worse in eyes with LHyperTD compared to eyes without (all P < .01). At follow-up, the same were worse in LHyperTD (all P < .01), as well as low luminance visual acuity (P < .01) and scotopic light sensitivity (P = .05).

conclusionLHyperTD are rare in normal and eAMD eyes and associate with mesopic and scotopic visual functions in addition to risk-indicating RMDA. Delayed RMDA reflects other factors other than LHyperTD including differences in disease stage. Our analysis of HT < 250 µm may inform other studies of early disease. LHyperTD are best utilized as imaging biomarkers for later stages of iAMD than ALSTAR2.

Indexed as

AgingColor VisionMacular DegenerationNight VisionVisual AcuityAgedAged, 80 and overDark AdaptationFemaleFluorescein AngiographyFollow-Up StudiesHumansMaleMesopic VisionMiddle AgedProspective Studies

Identifiers

PMID40849031
PMCPMC13264962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.